Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25533029 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL17822966 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL4508237 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL13799308 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL1401413 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL30244596 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3625523 | 0.96 | TSHR (0.38) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL17941156 | 0.92 | TSHR (0.42) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL25182441 | 0.92 | APLNR (0.35) | ALDH1A1TDP1APLNRNR1H2CYP2D6 | |
| SCHEMBL20535618 | 0.92 | APLNR (0.35) | ALDH1A1TDP1APLNRNR1H2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4626553-A2 | TLR7 AGONISTS AND ANTIBODY-DRUG-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250228944-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2025-07-17 | — | — | US | disclosed |
| EP-4580405-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | Oerth Bio LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050016-A9 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250073218-A1 | NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2025-03-06 | — | — | US | disclosed |
| US-20250057963-A1 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-02-20 | — | — | US | disclosed |
| US-12171831-B2 | Compounds and methods for the targeted degradation of bromodomain- containing proteins | ARVINAS OPERATIONS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2015000867-A1 | BENZOTHIOPHENE DERIVATIVES AS ESTROGEN RECEPTOR INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-01-08 | — | — | WO | disclosed |
| US-8791173-B2 | Ink composition for forming insulating film and insulating film formed from the ink composition | DIC CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| WO-2014108452-A1 | PROTEOLYSIS TARGETING CHIMERAS (PROTACS) DIRECTED TO THE MODULATION OF THE ESTROGEN RECEPTOR | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-17 | — | — | WO | disclosed |
| US-8758979-B2 | Photoresist composition | THE UNIVERSITY OF BIRMINGHAM (GB) | 2014-06-24 | — | — | US | disclosed |
| US-8758979-B2 | Photoresist composition | THE UNIVERSITY OF BIRMINGHAM (GB) | 2014-06-24 | — | — | US | disclosed |
| US-20120251953-A1 | PHOTORESIST COMPOSITION | THE UNIVERSITY OF BIRMINGHAM (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20120251953-A1 | PHOTORESIST COMPOSITION | THE UNIVERSITY OF BIRMINGHAM (GB) | 2012-10-04 | — | — | US | disclosed |
| WO-2011061501-A2 | PHOTORESIST COMPOSITION | THE UNIVERSITY OF BIRMINGHAM (GB) | 2011-05-26 | — | — | WO | disclosed |
| US-20110086946-A1 | INK COMPOSITION FOR FORMING INSULATING FILM AND INSULATING FILM FORMED FROM THE INK COMPOSITION | DIC CORPORATION (JP) | 2011-04-14 | — | — | US | disclosed |
| EP-2292707-A1 | INK COMPOSITION FOR FORMING AN INSULATING FILM AND AN INSULATING FILM FORMED FROM SAID INK COMPOSITION | DIC Corporation (JP) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073218-A1 | NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND | NLRP3, XIAP, NLRP1 | MEN1 3798/4885KMT2A 2385/4885TSHR 4781/4885 |
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ADRM1, CRBN, SNCA | MEN1 3954/4885KMT2A 1763/4885TSHR 2097/4885 |
| US-20250057963-A1 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | CDK10, CDK20, CDK9 | MEN1 3073/4885KMT2A 1003/4885TSHR 3173/4885 |
| US-20120251953-A1 | PHOTORESIST COMPOSITION | PPIF, PPIA, TUFM | MEN1 356/4885KMT2A 594/4885TSHR 4659/4885 |
| US-12171831-B2 | Compounds and methods for the targeted degradation of bromodomain- containing proteins | BRPF3, STUB1, BRDT | MEN1 2783/4885KMT2A 755/4885TSHR 3658/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | MEN1 3186/4885KMT2A 2541/4885TSHR 1899/4885 |
| US-20250228944-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | MEN1 2783/4885KMT2A 755/4885TSHR 3658/4885 |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | CRBN, STUB1, CUL1 | MEN1 1998/4885KMT2A 1480/4885TSHR 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.